VRPX

Virpax Pharmaceuticals Inc

VRPX, USA

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

https://www.virpaxpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VRPX
stock
VRPX

Virpax Pharmaceuticals stock hits 52-week low at $0.29 MSN

Read more →
VRPX
stock
VRPX

VRPX stock plunges to 52-week low, touches $1.07 Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-12-31)

Rating:

HOLD

Target Price:

$3

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.10

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

371.00 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-217.93 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.58% of the total shares of Virpax Pharmaceuticals Inc

1.

Geode Capital Management, LLC

(0.1311%)

since

2024/12/31

2.

HRT FINANCIAL LLC

(0.0794%)

since

2024/12/31

3.

Fidelity Extended Market Index

(0.0792%)

since

2025/03/31

4.

Virtu Financial LLC

(0.074%)

since

2024/12/31

5.

UBS Group AG

(0.041%)

since

2024/12/31

6.

XTX Topco Ltd

(0.0404%)

since

2024/12/31

7.

Fidelity Series Total Market Index

(0.0393%)

since

2025/03/31

8.

Fidelity Total Market Index

(0.0274%)

since

2025/03/31

9.

Tower Research Capital LLC

(0.0243%)

since

2024/12/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0207%)

since

2025/03/31

11.

SBI Securities Co Ltd

(0.0084%)

since

2025/03/31

12.

NT Ext Equity Mkt Idx Fd - NL

(0.003%)

since

2025/03/31

13.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0023%)

since

2025/03/31

14.

Northern Trust Extended Eq Market Idx

(0.0018%)

since

2025/03/31

15.

NT Ext Equity Mkt Idx Fd - L

(0.0018%)

since

2025/03/31

16.

Morgan Stanley - Brokerage Accounts

(0.0016%)

since

2024/12/31

17.

Spartan Total Market Index Pool E

(0.0009%)

since

2025/03/31

18.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0005%)

since

2025/03/31

19.

NT Ext Eq Mkt Indx Fd DC Lend T4

(0.0004%)

since

2024/12/31

20.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0004%)

since

2024/12/31

21.

Bank of America Corp

(0.0002%)

since

2024/12/31

22.

SSgA U.S. Total Market Index Strategy

(0.0001%)

since

2025/03/31

23.

Hantz Financial Services, INC.

(0%)

since

2024/12/31

24.

Citadel Advisors Llc

(0%)

since

2024/12/31

26.

TWO SIGMA SECURITIES, LLC

(0%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-12-31

EPS Actual

12.5

EPS Estimate

-6.75

EPS Difference

19.25

Surprise Percent

285.1852%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2024-12-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.